The principle that holds the whole concept together

Mytocel MSK is a point-of-care orthobiologic procedure that uses Autologous Micrograft Technology (AMT®), based on Rigenera® Technology, to deliver tissue-specific biological material — drawn from the patient's own auricular cartilage — directly to an affected joint. That description, though, only becomes clinically meaningful once the founding design decision is understood: all tissue processing is entirely mechanical.

No enzymes are introduced. No cells are cultured. No laboratory is involved. The choice to disaggregate donor tissue by calibrated mechanical action alone is not a workflow convenience; it is the architectural premise on which every other property of the procedure depends. It determines what the injectable suspension contains, how that suspension is produced, where production can take place, and what the patient's experience looks like from biopsy to injection.

The result is an autologous cartilage micrograft suspension designed to retain cartilage-derived cellular and extracellular-matrix-associated material without enzymatic digestion or ex-vivo culture. How the device delivers that controlled preparation is where the concept moves from principle to practice.

How the Rigeneracons® device turns a biopsy into a biological suspension

The three 2.5 mm punch biopsies taken from the posterior auricular concha are placed into the Rigeneracons® SRT alongside 4 cc of saline. From that point, a single-use, Class IIa registered medical device takes over — and every engineering parameter it operates at is deliberate.

The device's helix rotates at a constant 80 RPM across a grid of 100 hexagonal cells, each fitted with six calibrated microblades. The operative threshold is 80 µm: fragments smaller than this pass through into suspension; material above the threshold continues to be processed until it does. That boundary is not incidental. At 80 µm, the mechanical action achieves tissue breakdown without generating the shear forces or localised disruption that would rupture cell membranes or strip extracellular-matrix components — which is precisely what 'without causing cellular disruption and maintaining cell viability' means in practice.

The single-use designation follows directly from the same logic. Microblade geometry determines cut-off precision; a blade that has completed one processing cycle cannot be certified to hold the same edge geometry after re-sterilisation. A compromised blade means an unpredictable cut-off, which means an unreliable suspension. The protocol instruction here is brief, but it encapsulates the entire engineering rationale.

Quality confirmation is immediate and visual. A turbid — cloudy — suspension signals that intact micrografts are present in the extracted solution. A clear result indicates insufficient disaggregation and an inadequate biological payload. Turbidity is the procedure's front-line quality-assurance check, and it emerges naturally from the mechanical principle the whole device is designed to protect.

What the mechanical process actually preserves in the AMT® suspension

The injectable suspension that emerges from the Rigeneracons® SRT is not a purified cell fraction. It is a heterogeneous solution carrying both the cellular constituents and extracellular-matrix (ECM) components of the original auricular cartilage — together, in their native, tissue-specific state.

That heterogeneity is deliberate. Auricular cartilage ECM is not an inert structural filler: it houses collagen, proteoglycans, and matrix-associated signalling molecules — the biological environment in which the cells naturally reside. Separating those components, or discarding the matrix to produce a cleaner cell preparation, would yield a simpler product but a less faithful one. The AMT® solution preserves that complexity intact, meaning the cellular fraction arrives at the target joint still within the molecular context of its origin tissue rather than stripped of it.

Because the source material is the patient's own posterior auricular cartilage and no allogeneic additive or culture medium is introduced at any stage, the suspension is tissue-specific in a precise sense: it reflects that individual's donor-site biology, not a standardised or pooled preparation. Published peer-reviewed evidence (Bioengineering, 2023) reported encouraging safety and KOOS outcomes for autologous auricular cartilage micrografts in a small prospective early-stage knee osteoarthritis cohort, though the contribution of individual biological components to outcomes in the joint has not yet been fully characterised in controlled studies.

That preserved composition — cells and ECM held together, unaltered — is only realisable because the processing step introduces no chemistry that could disturb it.

How mechanical preparation differs from enzymatic and culture-based approaches

Ex-vivo cell culture introduces a category of problem that mechanical preparation does not encounter. When cells are expanded in a laboratory, they are removed from their native biological context and replicated across multiple generations before being returned to the patient. Phenotypic drift — the gradual shift in cell behaviour during repeated division — is a documented concern with expanded preparations. Beyond biology, expansion demands certified laboratory infrastructure, processing time measured in days, and the regulatory scrutiny that attaches to ex-vivo manipulation. None of that sits inside a point-of-care workflow.

Enzymatic digestion raises a distinct issue: the chemical agents used to dissociate tissue can denature surface receptors and degrade matrix constituents in the same action that breaks the tissue apart. As section 3 established, the ECM is not a byproduct to be discarded — it is part of what makes the suspension tissue-specific. Chemistry that strips it defeats the preparation's purpose.

Mechanical processing avoids both types of additional processing in the Mytocel MSK workflow. No laboratory, no culture medium, no chemical digestion. The three biopsies enter the Rigeneracons® SRT; the suspension — cells and ECM held together as they existed in the donor tissue — is ready within the same session. The choice of a purely mechanical approach is, in this sense, a consequence of what needs to be preserved rather than a preference for one method over another.

The point-of-care workflow that mechanical preparation enables

For the patient, Mytocel MSK resolves to a single outpatient appointment: a brief biopsy taken from behind the ear, a period of chair-side processing, and an injection into the affected joint — all within roughly 30 minutes, with no second visit to collect a prepared product and no overnight stay.

The donor site itself is designed to be as unobtrusive as the procedure. Three 2.5 mm biopsies from the posterior auricular concha are expected to heal over roughly one to two weeks without sutures; individual healing and scarring can vary — a minor anatomical exchange relative to the joint treatment being pursued.

Protocol discipline extends through to the moment of administration. Once the AMT® suspension has been disaggregated, the guidance is to draw it into a needleless Luer-Slip syringe using minimal force — a deliberate step to avoid disturbing the progenitor cells the mechanical processing preserved. Turbidity of the extracted solution serves as a front-line visual check that intact micrografts are present; a clear solution indicates insufficient disaggregation and an inadequate biological payload.

One specific contraindication follows the same logic. Active systemic infection warrants deferral because it may introduce proinflammatory cytokines and infection-modified cells into the suspension, compromising the biological quality of material that the entire preparation was designed to protect. That restriction is, in practice, a downstream expression of the same principle governing the processing step: the biological value of the AMT® solution depends on the integrity of the patient's own tissue from biopsy through to administration.

Clinical evidence supporting the procedure to date

The evidence that exists is specific and encouraging. Published in Bioengineering in 2023, Tsoukas et al. evaluated autologous auricular cartilage micrografts obtained via the AMT® procedure in patients with early-stage knee osteoarthritis, concluding that the approach represents "an effective and safe protocol" for this population. Marcarelli et al. (2021) provides further supporting clinical and mechanistic data within the same technology platform.

Wider deployment adds a layer of procedural confidence: Rigenera® Technology — the basis for the AMT® preparation — has been applied in over 450,000 treatments across more than 70 countries. That scale reflects a mature protocol operating within established medical-device regulation, though it constitutes procedural experience rather than a substitute for controlled-trial evidence.

Larger randomised controlled trials are needed to confirm long-term outcomes; early-stage knee osteoarthritis is the best-characterised indication in the current evidence base, and results from this population should not be carried across to other joints or more advanced disease stages without equivalent study data.

For patients presenting at that early stage, the published safety profile, combined with a preparation method that keeps the patient's own tissue-specific biological material intact from biopsy through to administration, positions Mytocel MSK as a well-grounded, point-of-care option — one that merits a specialist assessment to determine individual suitability.